Stoke Therapeutics, Inc. (STOK) Dividend History

Stoke Therapeutics, Inc. is a biotechnology company focused on developing therapies for genetic disorders by leveraging its proprietary platform to modulate gene expression. The company aims to address underlying genetic causes of diseases through precision oligonucleotide-based interventions.

45 Wiggins Avenue, Bedford, MA, 01730
Phone: 781-430-8200
Website: https://www.stoketherapeutics.com

Dividend History

Stoke Therapeutics, Inc. currently does not pay dividends

Company News

  • Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 $22.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 $35.00 Sumant Kulkarni Canaccord Genuity Lowers Buy $20.00 $21.00 Joseph Stringer Needham Maintains Buy $22.00 $22.00 Joseph Stringer Needham Maintains Buy $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

    Benzinga
  • Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: ATRA
  • Stoke Therapeutics' stock soars as positive data shows potential for their lead drug candidate, STK-001, in treating Dravet syndrome. Read here for more details.

    Seeking Alpha
  • This small-cap biotech might be a hidden gem.

    The Motley Fool
    Featured Companies: ACAD
Page data last updated 07/23/2025 09:39:38 UTC